News
CODX
1.150
-0.86%
-0.010
Weekly Report: what happened at CODX last week (0415-0419)?
Weekly Report · 1d ago
Elevance Health (ELV) Beats Q1 Earnings Estimates
NASDAQ · 5d ago
Weekly Report: what happened at CODX last week (0408-0412)?
Weekly Report · 04/15 12:00
Co-Diagnostics, Inc. Inaugurates New Manufacturing Facility in Utah with Ribbon Cutting Event
Ribbon-cutting included support from Mayor Wood of South Salt Lake and other dignitaries. Co-Diagnostics, Inc. Held the ribbon cutting event for its new manufacturing facility in the City of Salt Lake. The facility has been designed to manufacture the Co-Dx Pro™ instrument and test cups for the new platform.
Barchart · 04/12 08:30
Weekly Report: what happened at CODX last week (0401-0405)?
Weekly Report · 04/08 12:07
Co-Diagnostics, Inc. Appoints Richard Abbott As President, Concurrent With The Co Naming David Nielsen To Be Its Chief Operations Officer
Co-Diagnostics, Inc. Named Richard Abbott as President of the company. Co-Dx has a unique, patented platform for the development of molecular diagnostic tests. The Company also named David Nielsen, Christopher Thurston, and Seth Egan to key positions.
Benzinga · 04/04 13:31
*Co-Diagnostics Names David Nielsen as Chief Ops Officer and Christopher Thurston as Chief Technology Officer >CODX
Dow Jones · 04/04 13:31
CO-DIAGNOSTICS INC: BOARD OF DIRECTORS APPOINTED RICHARD ABBOTT AS PRESIDENT OF CO-DIAGNOSTICS, INC.
Reuters · 04/04 13:30
Press Release: Co-Diagnostics, Inc. Appoints New President and Other C-Level Positions
Co-Diagnostics, Inc. Appoints New President and Other C-Level Positions. Co-Dx is a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests. Richard Abbott is appointed President of Co- Diagnostics. The Company also names David Nielsen as Chief Operations Officer and Christopher Thurston as Chief Technology Officer.
Dow Jones · 04/04 13:30
*Co-Diagnostics, Inc. Appoints New Pres and Other C-Level Positions >CODX
Dow Jones · 04/04 13:30
*Co-Diagnostics: Richard Abbott Appointed as Pres >CODX
Dow Jones · 04/04 13:30
Peering Into Co-Diagnostics's Recent Short Interest
Co-Diagnostics's short percent of float has risen 12.61% since its last report. The company has 381 thousand shares sold short, which is 1.25% of all regular shares available for trading. Short interest is the number of shares that have been sold short but have not yet been covered.
Benzinga · 04/02 17:45
Weekly Report: what happened at CODX last week (0325-0329)?
Weekly Report · 04/01 12:03
Weekly Report: what happened at CODX last week (0318-0322)?
Weekly Report · 03/25 12:07
Weekly Report: what happened at CODX last week (0311-0315)?
Weekly Report · 03/18 12:05
Co-Diagnostics Inc Welcomes Richard Abbott as New President
TipRanks · 03/15 20:24
Co-Diagnostics Is Maintained at Neutral by HC Wainwright & Co.
Dow Jones · 03/15 10:57
Co-Diagnostics Price Target Cut to $2.50/Share From $3.00 by HC Wainwright & Co.
Dow Jones · 03/15 10:57
HC Wainwright & Co. Maintains Neutral on Co-Diagnostics, Lowers Price Target to $2.5
Benzinga · 03/15 10:49
Maintaining Hold on Co-Diagnostics Amid Revenue Decline and Potential EUA Boost
TipRanks · 03/15 10:27
More
Webull provides a variety of real-time CODX stock news. You can receive the latest news about Co-Diagnostics Inc through multiple platforms. This information may help you make smarter investment decisions.
About CODX
Co-Diagnostics, Inc. is a molecular diagnostics company, which develops, manufactures and markets diagnostics technologies. The Company’s technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious disease. Its diagnostics systems enable dependable, low-cost, molecular testing for organisms and genetic diseases by automating or simplifying historically complex procedures in both the development and administration of tests. It is developing a portable diagnostic device and test system designed for point-of-care and at-home use. The system consists of its PCR instrument that it refers to as the Co-Dx PCR Pro instrument, its proprietary diagnostic test cup system and a mobile application to be installed on the user’s mobile device.